UK markets closed

Centessa Pharmaceuticals plc (CNTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.6000-0.1200 (-3.23%)
As of 03:40PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 366.09M
Enterprise value -10.56M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.98
Enterprise value/revenue N/A
Enterprise value/EBITDA 1.03

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-65.49%
S&P500 52-week change 3-9.23%
52-week high 311.1900
52-week low 32.8850
50-day moving average 33.6342
200-day moving average 34.4245

Share statistics

Avg vol (3-month) 3119.1k
Avg vol (10-day) 3226.82k
Shares outstanding 594.6M
Implied shares outstanding 6N/A
Float 835.15M
% held by insiders 13.37%
% held by institutions 180.38%
Shares short (12 Jan 2023) 41.81M
Short ratio (12 Jan 2023) 417.16
Short % of float (12 Jan 2023) 4N/A
Short % of shares outstanding (12 Jan 2023) 41.92%
Shares short (prior month 14 Dec 2022) 41.86M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-25.56%
Return on equity (ttm)-50.71%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -223.1M
Net income avi to common (ttm)-233.81M
Diluted EPS (ttm)-2.2950
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)444.84M
Total cash per share (mrq)4.7
Total debt (mrq)68.2M
Total debt/equity (mrq)18.29
Current ratio (mrq)12.49
Book value per share (mrq)3.94

Cash flow statement

Operating cash flow (ttm)-205.41M
Levered free cash flow (ttm)-111.9M